Summary of the proceedings of the United States–Japan lung cancer clinical trials summit: San Francisco, CA, 20–22 November, 1998

Leigh, Bryan R.; Gandara, David R.; Crowley, John; Furuse, Kiyoyuki; Livingston, Robert B.; Fukushima, Masanori; Coltman, Charles A.

doi:10.1016/s0169-5002(99)00037-9

Cited by 1 publication

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 1998, SWOG established a collaboration with Japanese investigators of lung cancer. The purpose was to facilitate standardization of clinical trials and to allow for collaboration (28). With the hypothesis that ethnic related pharmacogenomics could account for differences in clinical outcomes despite similar treatment regimes, SWOG prospectively designed three phase three trials-The Four-Arm Cooperative Study (FACS), LC00-03 and S0003 in advanced stage NSCLC, each with a common arm carboplatin/paclitaxel (29)(30)(31).…”

Section: Non-small Cell Lung Cancermentioning

confidence: 99%

“…This was despite numerically higher dose reductions (51% vs. 26% in LC00-03 and S0003 respectively, P=0.63) and more patients receiving the full six cycles of carboplatin/paclitaxel (29% vs. 36.5% in LC00-03 and S0003 respectively, P<0.0001). The dose reduction data from FACS was not available for comparison (28)(29)(30)(31)(32)(33) (Table 1).…”

Section: Non-small Cell Lung Cancermentioning

confidence: 99%

See 1 more Smart Citation

Different treatment efficacies and side effects of cytotoxic chemotherapy

Chong

Wang

et al. 2020

J Thorac Dis

View full text Add to dashboard Cite

Differences in efficacy and toxicity between Asian and Caucasian patients with lung cancer treated with systemic chemotherapy is increasingly recognised. This is a major concern in the clinical setting as it influences outcomes and affect international harmonization of drug development. Interindividual variability of pharmacokinetics, where different genetic polymorphisms affect drug metabolism, transport, and receptor binding may account for the ethnic differences. Treatment efficacy and outcomes may also be explained by differences in diet and lifestyle, access to healthcare, cultural barriers and environmental exposure. Efforts made to design prospective studies investigating ethnic specific determinants to systemic therapy and individualise lung cancer treatment based on genetic makeup of patient are important.

show abstract